side effects of semaglutide and tirzepatide HCGTV: Webinar Snippet - 2026 Q1 ICD-10 Updates Switching from Semaglutide to Tirzepatide:

Kim and H

This approach leaves money on the table for injured patients who deserve maximum compensation for life-altering injuries

The most common side effects are nausea (44% of patients), diarrhea (30%), vomiting (24%), and constipation (24%)

Users aren't simply following a program - they're co-authoring it with experts who prioritize sustainable results

The first STEP trial (a series of large clinical trials that investigated who semaglutide helps and in what context) reported a 14.9% reduction in body weight over 72 weeks for participants taking 2.4 mg weekly

Some patients achieve meaningful weight loss at 1.7 mg and experience unacceptable tolerability at 2.4 mg, making 1.7 mg their optimal maintenance dose